tradingkey.logo

Ventyx Biosciences soars as report says Eli Lilly eyes $1 billion acquisition

ReutersJan 7, 2026 10:09 AM

Shares of drug developer Ventyx Biosciences VTYX.O surge 67% to $16.79 premarket

Eli Lilly LLY.N in advanced talks to buy VTYX for more than $1 billion, WSJ reported on Tuesday

Potential agreement will add drugs for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, to Lilly's pipeline

Stock soared roughly 220% to $25 immediately following the report on Tuesday, before Nasdaq temporarily halted trading on the stock

VTYX closed Tuesday up 28.5%, with a market cap of $717.15 million - data compiled by LSEG

VTYX stock more than quadrupled in 2025

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI